News

Pfizer, GSK to benefit as CDC panel endorses wider use of RSV shots
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to ...
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...
pharmaphorum3h
There's good news for RSV jab firms at delayed ACIP meeting
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
Mirage News3h
ACIP Expands Pfizer RSV Vaccine for At-Risk Adults 50-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...
The Pharma Letter4h
ACIP votes to expand recommendation for RSV vaccines
Advisory Committee on Immunization Practices (ACIP) has voted to expand its recommendation for the use of respiratory ...
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation
The U.S. Centers for Disease Control and Prevention’s vaccine panel voted to expand its recommendation for the use of ...
MedPage Today on MSN15h
ACIP Endorses RSV Vaccine for At-Risk Adults 50 and Up
The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...
GSK resolves patent lawsuit against Pfizer over RSV vaccines
British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
Morningstar16d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC ...
ACIP votes to expand recommendation for Pfizer’s RSV vaccine
Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand ...
Nasdaq16d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...